Biosimilar drugs could create billions in health care savings, study finds

(RAND Corporation) The US Food and Drug Administration is expected soon to approve rules for introduction of 'biosimilars,' generic versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis. A new analysis finds that biosimilars could cut spending on biologics in the United States by $44 billion over the next decade, creating savings for patients, health care payers and taxpayers.

http://www.eurekalert.org/pub_releases/2014-11/rc-bdc110314.php

Source: EurekAlert! - Medicine and Health - November 3, 2014 Category: Global & Universal Source Type: news